首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Translational Oncology

Translational Oncology杂志,由Neoplasia Press出版,于2007年创刊,Quarterly,出版语言English,ISSN:1944-7124,E-ISSN:1936-5233。

投稿咨询
Translational Oncology
Translational Oncology
Translational Oncology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
4.9
CiteScore
7.3
期刊收录
SCI、SCIE

Translational Oncology(中文译名:《转化肿瘤学》),ISSN:1944-7124,EISSN:1936-5233,是Neoplasia Press出版的国际性学术期刊,创刊于2007年,以Quarterly形式稳定发行,2026年总发文量约359篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.9,2025年期刊CiteScore为7.3,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Translational Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、GERMANY (FED REP GER)、South Korea、Japan、Italy、Canada等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMSUN YAT SEN UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、ZHEJIANG UNIVERSITY、CHINESE ACADEMY OF SCIENCES、FUDAN UNIVERSITY、SUNGKYUNKWAN UNIVERSITY (SKKU)等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 89 / 333

73.4

学科:ONCOLOGY SCIE Q2 88 / 333

73.72

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 78 / 322

75.9

学科:ONCOLOGY SCIE Q1 73 / 322

77.48


中国学者近期发文

1
PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implication

Author:Li, Jiajia; Mu, Degong; Li, Jin; Lan, Maozhuo; Wu, Wei; Zhang, Songling; Dai, Yun

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 68, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102757

2
Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patient

Author:Zhu, Li; Liu, Yang; Lan, Jianjun; Cai, Erdong; Sun, Dongmei; Liu, Jibin; Zong, Li; Cong, Zhirong

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 68, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102770

3
Transcriptomic and single-cell analyses reveal the prognostic value of ETV4 and its role in shaping the immune landscape of colorectal cance

Author:Meng, Ruipeng; Wang, Shilong; She, Zhanfei; Wang, Huaiming; Wu, Bo; Qiao, Yu; Chen, Pengyuan; Nargerel; Yang, Xiaofeng; Wang, Liang

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 68, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102775

4
Statins targeting mevalonate-geranylgeranyl diphosphate pathway inhibit proliferation in NK/T lymphoma by promoting pyroptosi

Author:Wang, Yingjun; Mei, Mei; Wang, Jieting; Wei, Lai; Zhang, Mengqian; Zhang, Mingzhi

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102747

5
EGR1 lactylation induces tumor cell senescence and immunosuppressive microenvironment in intrahepatic cholangiocarcinom

Author:Liang, Yuan; Zhang, Rui; Li, Yu; Wang, Hao; Qiao, Lei; Bu, Qingfa; Xu, Zibo; Liu, Zheng; Song, Ziyan; Huang, Tianning; Liu, Mu; Zhou, Jinren; Wang, Qi; Chen, Qiuyang; Lu, Ling

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102750

6
Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic respons

Author:Li, Yan; Chen, Jian; Li, Siyan; Tu, Gang; Tang, Lingfeng

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102749

7
Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathwa

Author:Abd El-Salam, Mohamed; Chen, Wu; Tang, Yan; Rao, Ting; Kang, Xuejia; Sun, Lifang; Han, Tiegang; Chen, Pengyu; Mossanen, Matthew; Cheng, Fan; Yang, Chun; Pan, Chong-Xian

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102753

8
Single-cell transcriptome analysis indicated that immune-related programmed cell death modification features could predict the clinical outcomes of patients with ovarian cance

Author:Sun, Jieyun; Jing, Li; Zhu, Xiangfei; Yang, Huan; Sun, Yu; Lu, Xiaoyuan; Liu, Zhao

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102752

9
Single-cell transcriptomic analysis reveals that the circRNA circGCLM promotes tumorigenesis and confers cisplatin resistance in NSCLC through the miR-505-3p/ERBB4 axi

Author:Ma, Yirou; Huang, Baiqing; Wang, Haiyang; Xue, Mengchao; Liu, Yiyang; Jin, Yibo; Wang, Chunping; Gu, Shaorui; Zhou, Yongxin

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102759

10
NF-κB signaling in hepatocellular carcinoma: Mechanisms of tumor progression, immune evasion, and therapeutic resistanc

Author:Yang, Ping; Li, Xiaoli; Yang, Lin; Xiao, Na; Ren, Lili; Ji, Mengmeng; Yang, Hua

Journal: TRANSLATIONAL ONCOLOGY. 2026; Vol. 67, Issue , pp. -. DOI: 10.1016/j.tranon.2026.102760


在线咨询

Translational Oncology

国际简称:TRANSL ONCOL参考译名:转化肿瘤学

年发文量:359 CiteScore:7.3 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:93.31%

杂志社联系方式:STE 800, 230 PARK AVE, NEW YORK, USA, NY, 10169

Translational Oncology